ACDC
A CBD-dominant cannabis cultivar derived from Cannatonic, valued for high CBD content and minimal intoxication.
ACDC is one of the few strains where the marketing roughly matches reality: it really does test high in CBD with very low THC, usually around a 20:1 ratio. That makes it genuinely useful for people who want cannabis without much of a head-change. Beyond that, claims about specific medical benefits are mostly extrapolated from general CBD research, not from studies on ACDC itself. No strain has clinical trials behind it — ACDC included.
Overview
ACDC is a CBD-dominant phenotype selected from Cannatonic, a hybrid bred by Resin Seeds in Spain in the late 2000s [1]. It became widely known in the United States after testing by analytical labs in California and Colorado consistently showed CBD:THC ratios near 20:1, with CBD often above 15% and THC below 1% Strong evidence[2]. That chemistry put ACDC at the center of the early medical-CBD movement, particularly for patients — including children with treatment-resistant epilepsy — looking for cannabis preparations that would not produce significant intoxication.
Unlike most popular cultivars, ACDC's reputation rests on a measurable chemical signature rather than aroma, yield, or potency in the THC sense. It is the strain people reach for when they explicitly do not want to get high.
Chemistry
ACDC is a Type III (CBD-dominant) chemotype Strong evidence. Cannabis plants fall into three main chemotypes based on the ratio of two enzymes that convert CBGA into either THCA or CBDA; Type III plants express the CBDA-synthase allele and accumulate CBD as their dominant cannabinoid [3].
Typical lab results for ACDC flower:
- CBD: 14-24%
- THC: 1-6% (often under 1% in well-selected cuts)
- Ratio: ~20:1 CBD:THC Strong evidence[2]
Terpenes in ACDC vary considerably between growers and labs. Reported dominant terpenes include myrcene, β-caryophyllene, and pinene, but there is no single 'ACDC terpene profile' that holds across cultivators Weak / limited. Claims that any specific terpene threshold (e.g. 'myrcene above 0.5% makes it sedating') predicts effects are folklore, not established science Disputed[4].
What is reliable about ACDC is the cannabinoid ratio. What is not reliable is its terpene profile — treat each batch as its own product.
Reported effects
There are no clinical trials on ACDC specifically, and no controlled studies comparing it to other cultivars No data. What follows is user-reported and should be read as such.
Users typically report:
- Minimal to no intoxication, even at moderate doses Anecdote
- Reduced anxiety or muscle tension Anecdote
- Mental clarity compared to THC-dominant strains Anecdote
These reports are consistent with what is known about CBD pharmacology in general: CBD is not intoxicating at typical doses, has anxiolytic effects in some controlled studies, and can blunt some of THC's psychoactive effects when co-administered Strong evidence[5][6]. But generalizing from 'CBD does X in a trial' to 'ACDC does X for you' skips several steps. Dose, route (smoked vs. vaporized vs. extracted), individual physiology, and expectation all matter.
The FDA has approved only one cannabis-derived CBD product (Epidiolex, purified CBD) for specific seizure disorders [7]. ACDC flower is not that product and has not been tested as a medical treatment.
Lineage
ACDC is generally described as a phenotype of Cannatonic, which Resin Seeds created by crossing a female MK Ultra with a male G13 Haze [1]. Cannatonic itself segregates into Type I, II, and III phenotypes; ACDC is the Type III selection Strong evidence.
Beyond that, lineage gets murky. The specific cut popularized in the US is variously attributed to growers in northern California, and several seed banks now sell 'ACDC' seeds whose relationship to the original clone is unverifiable Disputed. Because cannabis genetics are propagated informally and there is no central registry, two plants sold as ACDC at different dispensaries may not be genetically identical.
If the chemistry tests at ~20:1 CBD:THC, it is functionally ACDC for consumer purposes. If it doesn't, the name on the jar is just a name.
Cultivation basics
ACDC is considered moderately difficult to grow well Anecdote:
- Flowering time: 9-10 weeks indoors
- Structure: Tall, lanky, sativa-leaning growth that benefits from topping and trellising
- Yield: Moderate indoors (~400 g/m²); reports vary widely
- Sensitivity: Susceptible to powdery mildew in humid conditions; benefits from low-stress training
The more important cultivation issue with ACDC is genetic drift. Because ACDC seeds segregate (the parent line is heterozygous), only a small fraction of seedlings will express the high-CBD, low-THC phenotype. Serious growers work from verified clones, not seeds, and confirm chemotype with lab testing before committing to a mother plant Strong evidence. Buying 'ACDC seeds' and assuming the result will be CBD-dominant is a common and expensive mistake.
Marketing vs. reality
What's real:
- ACDC is genuinely CBD-dominant when sourced from a verified cut and tested batch Strong evidence.
- It produces little to no intoxication at typical doses Strong evidence.
- The cannabinoid ratio (~20:1) is consistent and measurable Strong evidence.
What's marketing or folklore:
- Specific medical claims ('ACDC treats anxiety/pain/epilepsy') — these extrapolate from CBD research, not from ACDC trials No data.
- Claims about a signature terpene profile or 'entourage effect' producing strain-specific outcomes Disputed[4].
- 'Indica/sativa' descriptors applied to ACDC — these categories don't reliably predict effects in any strain Disputed[8].
- Seed-grown ACDC reliably reproducing the parent's chemistry — it doesn't Strong evidence.
ACDC's honest value proposition is narrow and useful: a high-CBD, low-THC flower for people who want the ritual and route-of-administration of smoking or vaporizing cannabis without significant impairment. That's a real thing. Everything beyond that is extrapolation.
Sources
- Reported Sullum, J. (2014). 'The Marijuana Miracle: Why a Single Compound in Cannabis May Revolutionize Modern Medicine.' Reason Magazine, March 2014. ↗
- Reported Leafly Strain Database, ACDC entry, aggregated lab data from licensed testing facilities. ↗
- Peer-reviewed de Meijer, E.P.M., Bagatta, M., Carboni, A., et al. (2003). 'The Inheritance of Chemical Phenotype in Cannabis sativa L.' Genetics, 163(1), 335-346.
- Peer-reviewed Smith, C.J., Vergara, D., Keegan, B., Jikomes, N. (2022). 'The phytochemical diversity of commercial Cannabis in the United States.' PLOS ONE, 17(5): e0267498.
- Peer-reviewed Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., et al. (2011). 'Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.' Neuropsychopharmacology, 36(6), 1219-1226.
- Peer-reviewed Boggs, D.L., Nguyen, J.D., Morgenson, D., Taffe, M.A., Ranganathan, M. (2018). 'Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.' Neuropsychopharmacology, 43(1), 142-154.
- Government U.S. Food and Drug Administration (2018, updated). 'FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.' ↗
- Peer-reviewed Watts, S., McElroy, M., Migicovsky, Z., Maassen, H., van Velzen, R., Myles, S. (2021). 'Cannabis labelling is associated with genetic variation in terpene synthase genes.' Nature Plants, 7, 1330-1334.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannatonic — A high-CBD hybrid from Resin Seeds that helped launch the modern CBD-rich cannabis movemen...
- Charlotte's Web — The high-CBD hemp cultivar that reshaped public perception of cannabis as medicine in the...
- Harlequin — A CBD-dominant sativa-leaning strain that helped kickstart the modern high-CBD cannabis mo...